2024
Uterine fibroid–related infertility: mechanisms and management
Donnez J, Taylor H, Marcellin L, Dolmans M. Uterine fibroid–related infertility: mechanisms and management. Fertility And Sterility 2024, 122: 31-39. PMID: 38453041, DOI: 10.1016/j.fertnstert.2024.02.049.Peer-Reviewed Original ResearchUterine artery embolizationUterine fibroidsAssociation of fibroidsAdd-back therapyHeavy menstrual bleedingBaseline to weekOral GnRH antagonistPresence of fibroidsNon-surgical approachFocused ultrasoundFibroid volumeMyoma volumeArtery embolizationMenstrual bleedingCurrent management strategiesGnRH antagonistEchographic guidanceSurgical interventionFibroidsInfertilityMedical treatmentUterineWomenOptimal dosageSource of controversy
2022
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
Donnez J, Taylor H, Stewart E, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland J, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey 2022, 77: 741-742. DOI: 10.1097/ogx.0000000000001113.Peer-Reviewed Original Research
2012
A polymorphism in a let‐7 microRNA binding site of KRAS in women with endometriosis
Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS. A polymorphism in a let‐7 microRNA binding site of KRAS in women with endometriosis. EMBO Molecular Medicine 2012, 4: 206-217. PMID: 22307873, PMCID: PMC3376847, DOI: 10.1002/emmm.201100200.Peer-Reviewed Original ResearchConceptsEndometrial stromal cellsKRAS-variantCultured endometrial stromal cellsStromal cellsAbnormal endometrial growthDe novo endometriosisProgesterone receptor levelsRelatives of womenEndometrial xenograftsKRAS resultsLCS6 polymorphismEndometrial growthReproductive ageKRAS mutationsReceptor levelsMurine modelEndometriosisEndometriosis riskControl populationVariant allelesKRAS mRNAProtein expressionKRASWomenKRAS protein